Lymphatic filariasis – A result of neglect
Lymphatic filariasis is a serious parasitic infection causing certain parts of the body to swell up with thickened skin. The lymphatic system in the body which drains fluids from tissues and muscles gets affected causing the fluids to accumulate in the muscles and cause swelling. It also causes the skin to harden and develop a texture similar to that of an elephant and therefore, it is commonly known as elephantiasis.
Click here to Get free PDF Sample : http://www.marketresearchglobe.com/request-sample/243412
It has been reported to infect 947 million people spread in 54 countries and in most cases, it is caused by filarial parasites which are transported to the human body through mosquitoes like Culex, Anopheles and Aedes. In certain cases, surgery, radiation or other treatment procedures causing disruption of the normal functioning of the lymphatic system also act as causal reason for lymphatic filariasis. Three types of filarial worms, namely, Wucheria bancrofti, Brugia malayi, Brugia timori are responsible for elephantiasis. Adult worms travel to the lymphatic system to affect its functioning and in its lifetime of 6-8 years, produce millions of larvae that move to the bloodstream. Mosquitoes when bite an infected person, also get infected with the larvae which gets mature inside the body of the mosquito and transmits to different people with the mosquito acting as a carrier.
Lymphatic filariasis is asymptomatic and usually deforms the lower limbs, breasts or other genital organs. Though chronic, use of medication can reduce the effect of elephantiasis and prevent further diffusion of larvae into the bloodstream. In certain cases, pressure applying techniques to reduce swelling is also observed. Sometimes, the patient also undergoes surgery to get rid of the infected tissues. Besides, in tropical region where the infection is observed to be more common, mass drug administration schemes are followed where two medicine dosages are annually administered to the entire population as a preventive measure.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Elephantiasis (Lymphatic Filariasis) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Follow Us :
Twitter : https://twitter.com/marketrglobe